Go Pro

Weiss Ratings' Rating of Polaryx Therapeutics on 7/1/2026

On July 1, 2026, Weiss Ratings updated its outlook on Polaryx Therapeutics (NASDAQ:PLYX) with the action "Upgrade", setting a "Sell (E)" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Weiss Ratings

DateCompanyAction
7/2/2026
Wise Group plc stock logo
WSE
Wise Group
Upgrade
7/2/2026
NKLR
Terra Innovatum Global S.R.L.
Upgrade
7/2/2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
Downgrade
7/2/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
Downgrade
7/2/2026
Local Bounti Corporation stock logo
LOCL
Local Bounti
Upgrade
7/2/2026
Highway Holdings Limited stock logo
HIHO
Highway
Upgrade
More Ratings From Weiss Ratings